TABLE III.
Number and Registration Rates of Bone Tumors by Behavior, Histological Type, Sex, and Period at Diagnosis as Recorded in the Hiroshima Tumor Tissue Registry, 1973-2012*
| Male | Female | Total | |||||||||||||||||||
| 1973-1982 | 1983-1992 | 1993-2002 | 2003-2012 | 1973-2012 | 1973-1982 | 1983-1992 | 1993-2002 | 2003-2012 | 1973-2012 | 1973-2012 | |||||||||||
| Behavior and Histological Type | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors | Rate | No. of Tumors |
| Benign | |||||||||||||||||||||
| 1. Chondrogenic tumors | 198 (85.0%) | 15.7 | 323 (86.6%) | 24.4 | 283 (82.7%) | 24.1 | 252 (81.0%) | 24.0 | 1,056 (83.9%) | 21.7 | 159 (81.1%) | 12.2 | 295 (81.9%) | 20.8 | 298 (78.4%) | 22.3 | 266 (76.7%) | 21.4 | 1,018 (79.3%) | 19.1 | 2,074 (81.6%) |
| 2. Osteogenic tumors | 24 (10.3%) | 1.9 | 38 (10.2%) | 2.7 | 46 (13.5%) | 3.4 | 44 (14.1%) | 3.9 | 152 (12.1%) | 3.0 | 24 (12.2%) | 1.7 | 45 (12.5%) | 2.9 | 64 (16.8%) | 3.5 | 70 (20.2%) | 4.2 | 203 (15.8%) | 3.1 | 355 (14.0%) |
| 3. Fibrogenic tumors | 1 (0.4%) | 0.1 | 3 (0.8%) | 0.2 | 4 (1.2%) | 0.4 | 1 (0.3%) | 0.1 | 9 (0.7%) | 0.2 | 1 (0.5%) | 0.1 | 1 (0.3%) | 0.1 | 2 (0.5%) | 0.1 | 2 (0.6%) | 0.1 | 6 (0.5%) | 0.1 | 15 (0.6%) |
| 4. Fibrohistiocytic tumors | 1 (0.4%) | 0.1 | 1 (0.3%) | 0.1 | 2 (0.2%) | 0.0 | 2 (1.0%) | 0.2 | 4 (1.1%) | 0.3 | 3 (0.8%) | 0.2 | 1 (0.3%) | 0.0 | 10 (0.8%) | 0.2 | 12 (0.5%) | ||||
| 8. Vascular tumors | 5 (2.1%) | 0.3 | 3 (0.8%) | 0.2 | 4 (1.2%) | 0.2 | 7 (2.3%) | 0.4 | 19 (1.5%) | 0.3 | 3 (1.5%) | 0.2 | 7 (1.9%) | 0.4 | 4 (1.1%) | 0.2 | 5 (1.4%) | 0.2 | 19 (1.5%) | 0.3 | 38 (1.5%) |
| 9. Myogenic tumors | 1 (0.3%) | 0.2 | 1 (0.1%) | 0.0 | 1 (0.0%) | ||||||||||||||||
| 10. Lipogenic tumors | 1 (0.4%) | 0.1 | 1 (0.3%) | 0.1 | 2 (0.6%) | 0.1 | 1 (0.3%) | 0.1 | 5 (0.4%) | 0.1 | 1 (0.5%) | 0.1 | 1 (0.3%) | 0.1 | 4 (1.1%) | 0.2 | 1 (0.3%) | 0.0 | 7 (0.5%) | 0.1 | 12 (0.5%) |
| 11. Tumors of undefined neoplastic nature | 3 (1.3%) | 0.2 | 4 (1.1%) | 0.3 | 1 (0.3%) | 0.1 | 3 (1.0%) | 0.2 | 11 (0.9%) | 0.2 | 6 (3.1%) | 0.4 | 7 (1.9%) | 0.6 | 5 (1.3%) | 0.3 | 2 (0.6%) | 0.1 | 20 (1.6%) | 0.4 | 31 (1.2%) |
| 12. Miscellaneous tumors | 2 (0.6%) | 0.1 | 2 (0.6%) | 0.2 | 4 (0.3%) | 0.1 | 4 (0.2%) | ||||||||||||||
| Subtotal | 233 (100%) | 18.4 | 373 (100%) | 27.9 | 342 (100%) | 28.5 | 311 (100%) | 29.1 | 1,259 (100%) | 25.6 | 196 (100%) | 14.8 | 360 (100%) | 25.1 | 380 (100%) | 26.9 | 347 (100%) | 26.2 | 1,283 (100%) | 23.3 | 2,542 (100%) |
| Intermediate | |||||||||||||||||||||
| 1. Chondrogenic tumors | 1 (2.6%) | 0.1 | 5 (20.0%) | 0.5 | 13 (33.3%) | 1.4 | 5 (11.4%) | 0.6 | 24 (16.4%) | 0.6 | 4 (16.0%) | 0.3 | 10 (27.8%) | 0.9 | 5 (14.7%) | 0.5 | 19 (15.1%) | 0.4 | 43 (15.8%) | ||
| 2. Osteogenic tumors | 1 (2.3%) | 0.0 | 1 (0.7%) | 0.0 | 1 (0.4%) | ||||||||||||||||
| 3. Fibrogenic tumors | 1 (2.6%) | 0.1 | 1 (0.7%) | 0.0 | 1 (0.4%) | ||||||||||||||||
| 4. Fibrohistiocytic tumors | 1 (2.6%) | 0.1 | 3 (12.0%) | 0.2 | 1 (2.6%) | 0.0 | 5 (3.4%) | 0.1 | 4 (16.0%) | 0.3 | 1 (2.8%) | 0.1 | 5 (4.0%) | 0.1 | 10 (3.7%) | ||||||
| 6. Osteoclastic giant cell rich tumors | 35 (92.1%) | 2.7 | 17 (68.0%) | 1.3 | 22 (56.4%) | 1.5 | 38 (86.4%) | 2.8 | 112 (76.7%) | 2.1 | 31 (100%) | 2.2 | 17 (68.0%) | 1.1 | 24 (66.7%) | 1.7 | 28 (82.4%) | 2.1 | 100 (79.4%) | 1.8 | 212 (77.9%) |
| 8. Vascular tumors | 2 (5.1%) | 0.2 | 2 (1.4%) | 0.0 | 1 (2.8%) | 0.1 | 1 (2.9%) | 0.1 | 2 (1.6%) | 0.0 | 4 (1.5%) | ||||||||||
| 12. Miscellaneous tumors | 1 (2.6%) | 0.1 | 1 (0.7%) | 0.0 | 1 (0.4%) | ||||||||||||||||
| Subtotal | 38 (100%) | 2.9 | 25 (100%) | 1.9 | 39 (100%) | 3.3 | 44 (100%) | 3.5 | 146 (100%) | 2.9 | 31 (100%) | 2.2 | 25 (100%) | 1.7 | 36 (100%) | 2.7 | 34 (100%) | 2.7 | 126 (100%) | 2.3 | 272 (100%) |
| Malignant | |||||||||||||||||||||
| 1. Chondrogenic tumors | 6 (13.3%) | 0.4 | 27 (31.8%) | 1.6 | 17 (23.3%) | 0.9 | 22 (26.2%) | 1.0 | 72 (25.1%) | 1.1 | 16 (36.4%) | 1.1 | 16 (34.0%) | 0.9 | 13 (25.0%) | 0.6 | 18 (23.7%) | 0.9 | 63 (28.8%) | 0.9 | 135 (26.7%) |
| 2. Osteogenic tumors | 23 (51.1%) | 1.9 | 33 (38.8%) | 2.5 | 31 (42.5%) | 2.3 | 27 (32.1%) | 2.5 | 114 (39.7%) | 2.3 | 13 (29.5%) | 0.9 | 20 (42.6%) | 1.4 | 26 (50.0%) | 1.8 | 28 (36.8%) | 2.6 | 87 (39.7%) | 1.6 | 201 (39.7%) |
| 3. Fibrogenic tumors | 1 (1.2%) | 0.1 | 1 (1.4%) | 0.0 | 2 (0.7%) | 0.0 | 1 (2.3%) | 0.1 | 1 (1.3%) | 0.0 | 2 (0.9%) | 0.0 | 4 (0.8%) | ||||||||
| 4. Fibrohistiocytic tumors | 2 (4.4%) | 0.2 | 2 (2.4%) | 0.1 | 12 (16.4%) | 0.6 | 7 (8.3%) | 0.2 | 23 (8.0%) | 0.3 | 2 (4.5%) | 0.1 | 2 (3.8%) | 0.1 | 6 (7.9%) | 0.3 | 10 (4.6%) | 0.1 | 33 (6.5%) | ||
| 6. Osteoclastic giant cell rich tumors | 2 (4.4%) | 0.1 | 6 (7.1%) | 0.4 | 8 (2.8%) | 0.1 | 2 (4.5%) | 0.1 | 4 (8.5%) | 0.2 | 6 (2.7%) | 0.1 | 14 (2.8%) | ||||||||
| 7. Notochordal tumors | 4 (8.9%) | 0.3 | 7 (8.2%) | 0.4 | 5 (6.8%) | 0.2 | 14 (16.7%) | 0.5 | 30 (10.5%) | 0.3 | 3 (6.8%) | 0.2 | 1 (1.9%) | 0.0 | 13 (17.1%) | 0.7 | 17 (7.8%) | 0.2 | 47 (9.3%) | ||
| 8. Vascular tumors | 3 (3.5%) | 0.1 | 1 (1.2%) | 0.0 | 4 (1.4%) | 0.0 | 2 (3.8%) | 0.1 | 2 (2.6%) | 0.1 | 4 (1.8%) | 0.0 | 8 (1.6%) | ||||||||
| 9. Myogenic tumors | 1 (1.4%) | 0.1 | 1 (0.3%) | 0.0 | 3 (3.9%) | 0.1 | 3 (1.4%) | 0.0 | 4 (0.8%) | ||||||||||||
| 11. Tumors of undefined neoplastic nature | 3 (6.7%) | 0.2 | 2 (2.4%) | 0.1 | 5 (1.7%) | 0.1 | 2 (4.5%) | 0.1 | 2 (3.8%) | 0.1 | 4 (1.8%) | 0.1 | 9 (1.8%) | ||||||||
| 12. Miscellaneous tumors | 5 (11.1%) | 0.4 | 4 (4.7%) | 0.3 | 6 (8.2%) | 0.4 | 13 (15.5%) | 1.2 | 28 (9.8%) | 0.5 | 5 (11.4%) | 0.4 | 7 (14.9%) | 0.6 | 6 (11.5%) | 0.5 | 5 (6.6%) | 0.2 | 23 (10.5%) | 0.4 | 51 (10.1%) |
| Subtotal | 45 (100%) | 3.5 | 85 (100%) | 5.6 | 73 (100%) | 4.6 | 84 (100%) | 5.5 | 287 (100%) | 4.9 | 44 (100%) | 3.0 | 47 (100%) | 3.1 | 52 (100%) | 3.2 | 76 (100%) | 4.8 | 219 (100%) | 3.5 | 506 (100%) |
| Total | 316 | 483 | 454 | 439 | 1,692 | 271 | 432 | 468 | 457 | 1,628 | 3,320 | ||||||||||
*
The values in the “Rate” columns indicate the age-standardized registration rate per million population according to the Segi’s World Standard Population. Patients whose age was unknown were excluded.